| Trial ID: | L5214 |
| Source ID: | NCT01877590
|
| Associated Drug: |
Alpha-Lipoic Acid
|
| Title: |
Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes|Coronary Artery Disease|Left Ventricular Mass
|
| Interventions: |
DRUG: alpha-lipoic acid
|
| Outcome Measures: |
Primary: Alpha-lipoic acid regress the left ventricular mass, Alpha-lipoic acid 600 mg daily for one year., one year | Secondary: The change of endothelial dysfunction before and after alpha-lipoic acid intervention., one year
|
| Sponsor/Collaborators: |
Sponsor: Wuhan General Hospital of Guangzhou Military Command
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
66
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2013-11
|
| Completion Date: |
2015-07
|
| Results First Posted: |
|
| Last Update Posted: |
2015-08-21
|
| Locations: |
Wuhan General Hospital, Wuhan, Hubei, 430070, China
|
| URL: |
https://clinicaltrials.gov/show/NCT01877590
|
